Viridian Therapeutics, Inc.\DE (VRDN) Other Non-Current Liabilities (2014 - 2026)

Viridian Therapeutics, Inc.\DE's Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 563.48% year-over-year to $12.5 million in Q1 2026; TTM through Mar 2026 was $12.5 million, a 563.48% increase from a year earlier, with the FY2025 full-year figure at $20.0 million, up 767.85% from the prior year.
• Other Non-Current Liabilities declined to $12.5 million in Q1 2026 per VRDN's latest filing, from $20.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $20.0 million in Q4 2025 and bottomed at $813000.0 in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $1.5 million (2023), against an average of $3.2 million.
• Biggest YoY gain for Other Non-Current Liabilities was 3112.12% in 2022; the steepest drop was 64.26% in 2022.
• Year by year, Other Non-Current Liabilities stood at $1.2 million in 2022, then dropped by 15.61% to $989000.0 in 2023, then jumped by 133.37% to $2.3 million in 2024, then soared by 767.85% to $20.0 million in 2025, then sank by 37.59% to $12.5 million in 2026.
• Per Business Quant, the three latest VRDN Other Non-Current Liabilities figures stand at $12.5 million (Q1 2026), $20.0 million (Q4 2025), and $2.6 million (Q3 2025).